Analysed CENTURY THERAPEUTICS INC (IPSC:NASDAQ) News Sources
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
30-04-2026
yahoo.com
Century Therapeutics Reports First Quarter Financial Results and Business Updates
13-05-2026
yahoo.com
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
14-05-2026
yahoo.com
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
08-06-2026
yahoo.com
Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813
10-06-2026
yahoo.com
Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation
13-06-2026
yahoo.com
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight
22-06-2026
yahoo.com
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
09-07-2026
yahoo.com
What is the current price of CENTURY THERAPEUTICS INC (IPSC:NASDAQ)?
The current price of CENTURY THERAPEUTICS INC (IPSC:NASDAQ) is $2.01.
CENTURY THERAPEUTICS INC (IPSC:NASDAQ) absolute price change since previous trading day?
The absolute price change of CENTURY THERAPEUTICS INC (IPSC:NASDAQ) since the previous trading day is $-0.08.
CENTURY THERAPEUTICS INC (IPSC:NASDAQ) percentage price change since previous trading day?
The percentage price change of CENTURY THERAPEUTICS INC (IPSC:NASDAQ) since the previous trading day is -3.8278%.
What is the most recent average sentiment score for CENTURY THERAPEUTICS INC (IPSC:NASDAQ)?
The most recent average sentiment score for CENTURY THERAPEUTICS INC (IPSC:NASDAQ) is 85 out of 100.
What is the most recent average sentiment for CENTURY THERAPEUTICS INC (IPSC:NASDAQ)?
The most recent sentiment for CENTURY THERAPEUTICS INC (IPSC:NASDAQ) is .
SEC-8K** Filing Available For CENTURY THERAPEUTICS INC (IPSC:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.